Key Takeaways ISRG formed a golden crossover as shares jumped 23% on strong procedures and platform momentum.Robust growth across da Vinci, Ion and SP systems highlighted rising utilization and global uptake.Rapid dV5 adoption, expanding indications and digital tools reinforced ISRG's long-term growth narrative.Intuitive Surgical (ISRG) entered a new phase of bullish momentum on Dec. 3, 2025, when it formed a golden crossover — a technical chart pattern in which the 50-day moving average crosses the 200-day ...

Key Takeaways Barrick has soared 101.1% in 6 months, beating industry and S&P 500 gains on record gold price momentum.Key growth projects like Goldrush, Lumwana and Reko Diq aim to boost long-term gold and copper output.Rising costs and tepid 2025 production outlook may weigh on margins despite strong earnings forecasts.Barrick Mining Corporation’s (B) shares have rocketed 101.1% in the past six months, thanks to the rally in gold prices to historic highs amid economic, geopolitical and tariff-related uncer ...

Core Insights - Medtronic has regained momentum, with its stock price expected to rise, reflecting a bottoming process over several years [2][3] - The stock is projected to rally over the coming quarters and years, supported by modest growth, healthy margins, cash flow, and capital returns [3] - Analysts indicate accumulation trends, with strong Q2 results and guidance affirming strength and capital returns for fiscal year 2026 and beyond [3] Financial Performance - Medtronic's stock price could advance by 20% to 30%, driven by a favorable growth outlook and mid-single-digit growth in fiscal year 2026 [4][5] - The company reported $8.96 billion in net revenue for Q2, marking a 6.6% year-over-year increase, which outpaced consensus expectations [8] - Organic growth was up 5.5%, with the Cardiovascular portfolio growing by 10.8%, and diabetic sales increasing by 10.3% year-over-year [9] Capital Returns - Capital returns are significant, with a reliable dividend yield of 2.95% and a payout ratio of approximately 50%, ensuring sustainability [6] - Medtronic is recognized as a Dividend Aristocrat, having increased dividends for over 40 consecutive years, alongside earnings growth and a healthy balance sheet [7] - Share buybacks are ongoing, expected to continue reducing the share count incrementally each quarter [7]

Group 1: Market Overview - The recent Fed rate cut in October and new trade deals between the US and China have created bullish signals for three Made in USA coins, despite the broader market being down nearly 7% week-on-week [1] - These three tokens are showing strong technical setups, with some indicating early breakout signs and others gaining momentum for potential upside in November 2025 [1] Group 2: DigiByte (DGB) Analysis - DigiByte, launched in 2014, has seen a 36.8% increase in the past 24 hours, indicating renewed momentum after a period of sideways movement with three-month gains of approximately +2.3% [2] - A "golden crossover" is anticipated on the 12-hour chart, where the 20-period Exponential Moving Average (EMA) approaches crossing above the 50-period EMA, suggesting potential sustained upward movement [3] - If the crossover occurs, DigiByte could target resistance levels between $0.0093 and $0.0097, representing an increase of roughly 11-15% from current levels, with a further target at $0.01054, a peak from July [4] Group 3: Support and Risk Levels for DigiByte - The first key support level for DigiByte is at $0.00733, with a further critical level at $0.00574, which could invalidate the bullish setup if breached [5] Group 4: Basic Attention Token (BAT) Analysis - Basic Attention Token (BAT), developed by Brendan Eich, is showing strong chart structures, with a 7% gain over the past week and a 22.6% increase over the last month, indicating a gradual recovery [7][8] - BAT is currently trading within a descending channel, a pattern that may reverse if the price breaks above its upper trendline [8]

Golden crossover for $ETH.What's next is obvious! https://t.co/uPUNAs7Chh ...

Core Viewpoint - Freeport-McMoRan Inc. (FCX) has shown strong performance with an 11.3% increase in shares over the past six months, outperforming both the Zacks Mining - Non Ferrous industry and the S&P 500, despite facing challenges such as higher expected unit costs and weaker sales volumes for copper and gold [1][6][26] Performance Summary - FCX's shares have gained 11.3% in the last six months, compared to a 1.3% rise in the industry and a 7.3% gain in the S&P 500 [1] - The company’s peers, Southern Copper Corporation (SCCO) and BHP Group Limited (BHP), have seen smaller gains of 0.8% and 4.9%, respectively [1] Financial Health - FCX generated operating cash flows of approximately $2.2 billion in Q2 2025 and has distributed $5.2 billion to shareholders since June 30, 2021 [12] - The company ended Q2 with $4.5 billion in cash and cash equivalents, $3 billion available under its revolving credit facility, and $1.5 billion under the PT-FI credit facility [12] - FCX's net debt stands at $1.5 billion, below its targeted range of $3-$4 billion, with a long-term debt-to-capitalization ratio of around 22.9% [13] Production and Expansion Plans - FCX is focused on expanding its copper output, with significant projects underway, including a concentrator expansion at Cerro Verde in Peru, expected to add 600 million pounds of copper annually [9] - The company is also evaluating a large-scale expansion at El Abra in Chile and conducting pre-feasibility studies in Arizona for further growth opportunities [10] Sales Volume and Pricing Trends - FCX's copper sales volumes increased by approximately 9% year-over-year in Q2 to 1,016 million pounds, with gold sales reflecting a 45% year-over-year growth [20] - However, the outlook for Q3 suggests a decline in copper sales volumes to 990 million pounds, indicating a 4% year-over-year decrease [21] Cost and Margin Outlook - FCX's average unit net cash cost per pound of copper decreased to $1.13 in Q2 from $1.73 a year earlier, but is expected to rise to $1.59 in Q3 due to higher costs and lower sales volumes [18][19] - The company anticipates that tariffs could increase the cost of goods purchased in the U.S. by approximately 5%, further impacting margins [19] Earnings Estimates - The Zacks Consensus Estimate for FCX's earnings in 2025 is $1.74, indicating a year-over-year growth of 17.6%, with expected growth of 33.8% in 2026 [22] Valuation - FCX is currently trading at a forward price/earnings ratio of 19.52X, which is a slight premium to the industry average of 19.13X [23] Investment Recommendation - Despite the positives of expansion activities and strong financial health, the recent decline in copper prices and weaker sales volume outlook suggest a cautious approach, recommending to hold the stock for current investors [26]

Core Viewpoint - Harmony Gold Mining Company Limited (HMY) has experienced a significant share price increase of 55.5% over the past six months, outperforming the Zacks Mining – Gold industry and the S&P 500, driven by rising gold prices and strong operational performance [1]. Group 1: Stock Performance - HMY's stock has outperformed its peers, with Gold Fields Limited (GFI) and DRDGOLD Limited (DRD) gaining 43% and 45.2%, respectively, during the same period [1]. - Technical indicators show that HMY stock surpassed its 200-day simple moving average (SMA) on January 15, 2025, indicating a bullish trend despite currently trading below the 50-day SMA [4]. Group 2: Growth Projects - HMY is South Africa's largest gold producer, with an output of approximately 1.56 million ounces in fiscal 2024, and has a diverse portfolio of gold development projects in South Africa and Papua New Guinea (PNG) [9]. - The Wafi-Golpu copper-gold project in PNG is expected to be transformative for HMY, with an estimated gold reserve of 13 million ounces, and negotiations are ongoing for a Mining Development Contract [9]. - The Eva Copper project in Australia, acquired in 2022, is anticipated to produce 55,000-60,000 tons of copper annually and is supported by conditional grant funding from the Queensland government [10]. Group 3: Financial Performance - HMY's adjusted earnings surged 120% year over year in fiscal 2024, driven by an 11% increase in average gold prices, with prices reaching $2,497 per ounce for the nine months ending March 31, 2025 [12]. - The company's net cash increased by approximately 53% to $592 million at the end of the third quarter of fiscal 2025, reflecting strong cash flow generation [13]. Group 4: Valuation - HMY is currently trading at a forward price/earnings ratio of 7.75X, which is about 41.7% lower than the industry average of 13.3X, indicating an attractive valuation [14]. - Both Harmony Gold and Gold Fields have a Value Score of B, while DRDGOLD has a Value Score of C, suggesting HMY's stock is appealing for value-seeking investors [14]. Group 5: Investment Outlook - The combination of advancing key development projects, rising gold prices, and a solid balance sheet positions HMY favorably for future growth, making it a strong buy recommendation [17].